Difference between revisions of "Etoposide (Vepesid)"
Jump to navigation
Jump to search
m |
m |
||
| (21 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Topoisomerase II inhibitor. | + | Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.<ref name="insert">[http://packageinserts.bms.com/pi/pi_etopophos.pdf Etoposide (Vepesid) package insert]</ref><ref>[[:File:Etoposide.pdf | Etoposide (Vepesid) package insert (locally hosted backup)]]</ref> |
<br>Route: IV, PO | <br>Route: IV, PO | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is established ''(work in progress)''== | ||
| + | *Non-Hodgkin lymphoma | ||
| + | **[[Follicular lymphoma]] | ||
| + | **[[Peripheral T-cell lymphoma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
| + | *[[Acute lymphoblastic leukemia, infant]] | ||
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
| Line 16: | Line 22: | ||
*[[Anaplastic large cell lymphoma]] | *[[Anaplastic large cell lymphoma]] | ||
*[[B-cell acute lymphoblastic leukemia]] | *[[B-cell acute lymphoblastic leukemia]] | ||
| + | *[[T-cell acute lymphoblastic leukemia]] | ||
*[[Burkitt lymphoma]] | *[[Burkitt lymphoma]] | ||
*[[Cholangiocarcinoma]] | *[[Cholangiocarcinoma]] | ||
| Line 25: | Line 32: | ||
*[[Ewing sarcoma]] | *[[Ewing sarcoma]] | ||
*[[Extranodal NK- and T-cell lymphoma, nasal type]] | *[[Extranodal NK- and T-cell lymphoma, nasal type]] | ||
| − | |||
*[[Gallbladder cancer]] | *[[Gallbladder cancer]] | ||
*[[Gestational trophoblastic neoplasia]] | *[[Gestational trophoblastic neoplasia]] | ||
*[[Hemophagocytic lymphohistiocytosis]] | *[[Hemophagocytic lymphohistiocytosis]] | ||
*[[HIV-associated lymphoma]] | *[[HIV-associated lymphoma]] | ||
| − | *[[Hodgkin lymphoma]] | + | *[[Classical Hodgkin lymphoma]] |
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | *[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | ||
*[[Kaposi sarcoma]] | *[[Kaposi sarcoma]] | ||
*[[Langerhans cell histiocytosis]] | *[[Langerhans cell histiocytosis]] | ||
*[[Low-grade glioma]] | *[[Low-grade glioma]] | ||
| + | **[[Low-grade glioma, pediatric]] | ||
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
*[[Mediastinal gray-zone lymphoma]] | *[[Mediastinal gray-zone lymphoma]] | ||
*[[Medulloblastoma]] | *[[Medulloblastoma]] | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
| + | *[[Neuroblastoma]] | ||
*[[NK- and T-cell lymphoma]] | *[[NK- and T-cell lymphoma]] | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
| + | **[[Non-small cell lung cancer, nonsquamous]] | ||
*[[Osteosarcoma]] | *[[Osteosarcoma]] | ||
*[[Ovarian cancer]] | *[[Ovarian cancer]] | ||
| − | |||
*[[Primary mediastinal B-cell lymphoma]] | *[[Primary mediastinal B-cell lymphoma]] | ||
*[[Rhabdomyosarcoma]] | *[[Rhabdomyosarcoma]] | ||
| Line 55: | Line 63: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://packageinserts.bms.com/pi/pi_etopophos.pdf Etoposide (Vepesid) package insert]<ref name="insert"></ref> | *[http://packageinserts.bms.com/pi/pi_etopophos.pdf Etoposide (Vepesid) package insert]<ref name="insert"></ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/etoposide.aspx Etoposide (Vepesid) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/etoposide.aspx Etoposide (Vepesid) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *11 | + | *1983-11-10: Initial FDA approval for refractory [[Testicular cancer | testicular tumors]]. ''(No supporting studies are cited)'' |
| − | * | + | *Uncertain date: Approed for [[small cell lung cancer]], in combination with cisplatin, as first-line treatment. ''(Based on Hainsworth et al. 1995)'' |
| + | ==History of changes in EMA indication== | ||
| + | *1980-07-09: EURD | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2012-02-22: New additional indication and a new dosage for the treatment of [[ovarian cancer]] which has progressed after cancer chemotherapy. | ||
| + | *2019-03-26: New indication for the treatment prior to tumor-specific T-cell infusion therapy. | ||
| + | |||
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' VP-16, VP-TEC, VP 16213 | + | *'''Code names:''' VP-16, VP-TEC, VP-16213 |
*'''Generic name:''' etoposide phosphate | *'''Generic name:''' etoposide phosphate | ||
*'''Brand names:''' | *'''Brand names:''' | ||
| Line 137: | Line 151: | ||
[[Category:Irritant]] | [[Category:Irritant]] | ||
| − | [[Category:Topoisomerase inhibitors]] | + | [[Category:Topoisomerase II inhibitors]] |
| + | [[Category:Acute lymphoblastic leukemia, infant medications]] | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
| Line 147: | Line 162: | ||
[[Category:Anaplastic large cell lymphoma medications]] | [[Category:Anaplastic large cell lymphoma medications]] | ||
[[Category:B-cell acute lymphoblastic leukemia medications]] | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
| + | [[Category:T-cell acute lymphoblastic leukemia medications]] | ||
[[Category:Burkitt lymphoma medications]] | [[Category:Burkitt lymphoma medications]] | ||
[[Category:Cholangiocarcinoma medications]] | [[Category:Cholangiocarcinoma medications]] | ||
| Line 161: | Line 177: | ||
[[Category:Hemophagocytic lymphohistiocytosis medications]] | [[Category:Hemophagocytic lymphohistiocytosis medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications]] |
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | [[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | ||
[[Category:Langerhans cell histiocytosis medications]] | [[Category:Langerhans cell histiocytosis medications]] | ||
[[Category:Low-grade glioma medications]] | [[Category:Low-grade glioma medications]] | ||
| + | [[Category:Low-grade glioma, pediatric medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Mediastinal gray-zone lymphoma medications]] | [[Category:Mediastinal gray-zone lymphoma medications]] | ||
[[Category:Medulloblastoma medications]] | [[Category:Medulloblastoma medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
| + | [[Category:Neuroblastoma medications]] | ||
| + | [[Category:Neuroendocrine carcinoma medications]] | ||
[[Category:NK- and T-cell lymphoma medications]] | [[Category:NK- and T-cell lymphoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Non-small cell lung cancer, nonsquamous medications]] | ||
[[Category:Osteosarcoma medications]] | [[Category:Osteosarcoma medications]] | ||
[[Category:Ovarian cancer medications]] | [[Category:Ovarian cancer medications]] | ||
| Line 184: | Line 204: | ||
[[Category:FDA approved in 1983]] | [[Category:FDA approved in 1983]] | ||
| + | [[Category:EMA approved in 1980]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 11:38, 6 January 2024
General information
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established (work in progress)
- Non-Hodgkin lymphoma
Diseases for which it is used
- Acute lymphoblastic leukemia, infant
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Carcinoma of unknown primary
- Adrenocortical carcinoma
- Adult T-cell leukemia-lymphoma
- Anaplastic glioma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- T-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- Cholangiocarcinoma
- CNS lymphoma
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Ewing sarcoma
- Extranodal NK- and T-cell lymphoma, nasal type
- Gallbladder cancer
- Gestational trophoblastic neoplasia
- Hemophagocytic lymphohistiocytosis
- HIV-associated lymphoma
- Classical Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Kaposi sarcoma
- Langerhans cell histiocytosis
- Low-grade glioma
- Mantle cell lymphoma
- Mediastinal gray-zone lymphoma
- Medulloblastoma
- Multiple myeloma
- Neuroblastoma
- NK- and T-cell lymphoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Primary mediastinal B-cell lymphoma
- Rhabdomyosarcoma
- Soft tissue sarcoma
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Transformed lymphoma
Patient drug information
- Etoposide (Vepesid) package insert[1]
- Etoposide (Vepesid) patient drug information (Chemocare)[3]
- Etoposide (Vepesid) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1983-11-10: Initial FDA approval for refractory testicular tumors. (No supporting studies are cited)
- Uncertain date: Approed for small cell lung cancer, in combination with cisplatin, as first-line treatment. (Based on Hainsworth et al. 1995)
History of changes in EMA indication
- 1980-07-09: EURD
History of changes in PMDA indication
- 2012-02-22: New additional indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy.
- 2019-03-26: New indication for the treatment prior to tumor-specific T-cell infusion therapy.
Also known as
- Code names: VP-16, VP-TEC, VP-16213
- Generic name: etoposide phosphate
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Aside | Beposid | Bioposide | Celltop | Citodox | Epocin | Eposid | Eposide |
| Eposido | Eposin | Epsidox | ETO | Etocris | Etomedac | Etonolver | Etopofos |
| Etopophos | Etopos | Etoposid | Etoposido | Etopoxan | Etopul | Etosid | Etosin |
| Eunades CS | Euvaxon | Exitop | Fytop | Fytosid | Labimion | Lastet | Lastet S |
| Neoplaxol | Nexvep | Onkoposid | Optasid | Percas | Posid | Posidon | Posyd |
| Riboposid | Sintopozid | Toposar | Toposide | Toposin | Topresid | Tosuben | Vepefos |
| Vepesid | Vepeside | Vepsid | Vepside | ||||
References
Categories:
- Drugs
- Intravenous medications
- Oral medications
- Irritant
- Topoisomerase II inhibitors
- Acute lymphoblastic leukemia, infant medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Carcinoma of unknown primary medications
- Adrenocortical carcinoma medications
- Adult T-cell leukemia-lymphoma medications
- Anaplastic glioma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- T-cell acute lymphoblastic leukemia medications
- Burkitt lymphoma medications
- Cholangiocarcinoma medications
- CNS lymphoma medications
- Diffuse large B-cell lymphoma medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Esophageal squamous cell carcinoma medications
- Ewing sarcoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Follicular lymphoma medications
- Gallbladder cancer medications
- Gestational trophoblastic neoplasia medications
- Hemophagocytic lymphohistiocytosis medications
- HIV-associated lymphoma medications
- Classical Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Langerhans cell histiocytosis medications
- Low-grade glioma medications
- Low-grade glioma, pediatric medications
- Mantle cell lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Medulloblastoma medications
- Multiple myeloma medications
- Neuroblastoma medications
- Neuroendocrine carcinoma medications
- NK- and T-cell lymphoma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Osteosarcoma medications
- Ovarian cancer medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- Rhabdomyosarcoma medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Transformed lymphoma medications
- Kaposi sarcoma medications
- FDA approved in 1983
- EMA approved in 1980
- WHO Essential Cancer Medicine